Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted...

PCRX : 21.56 (-0.78%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 21.56 (-0.78%)
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...

PCRX : 21.56 (-0.78%)
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

-- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 ...

PCRX : 21.56 (-0.78%)
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,...

PCRX : 21.56 (-0.78%)
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 21.56 (-0.78%)
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Restates Position that Pacira's Board Should Conduct Formal Sales Process of the Business

PCRX : 21.56 (-0.78%)
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment-- --PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries--...

PCRX : 21.56 (-0.78%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 21.56 (-0.78%)
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° -- -- Fewer iovera° patients required additional spine injections after 180 days -- --  No...

PCRX : 21.56 (-0.78%)

Barchart Exclusives

Down 50% in the Past Year, Wedbush Wants You to Buy the Dip in This Software Stock
Wedbush says that ServiceNow is a "stalwart" in the AI revolution. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar